关于 dose.wiki

一个关于精神活性物质及其效应的开放百科全书

dose.wiki 将来自减害与参考来源的关于精神活性物质的事实性知识综合为一个开放数据集。它旨在为精神药理学数据集建立一个开放标准，支持研究与教育。

267 篇物质条目： 剂量、持续时间、效应、相互作用、化学与各国法律地位。
233 篇主观效应条目： 意识改变状态的各个组成部分，从视觉漂移感到自我消解。
6,642 个再现作品： 再现主观效应的图片、视频和音频。
274 篇体验报告： 个人经历的第一人称记述。

来源与审校

物质文章中的事实知识汲取自科学家、心理航行者（psychonauts）和减害社区数十年的记录，收集自ten harm-reduction and reference resources。每篇文章都链接到为其提供依据的来源页面。

物质文章由LLM起草，剂量信息由软件从在线表格中转录。随后，真实的人类在数月的时间里对每一份输出进行了审阅和细致编辑。how articles are made深入解释了这一过程。

那么，我们为什么在流程中使用LLM？原因有几个，但主要是速度、实用性和可复现性。Josie Kins，本项目的联合创始人、PsychonautWiki的创始人以及众多其他类似项目的创始人，拥有与人类团队一起手工编写物质百科全书的现实经验。我们知道这需要付出什么。那是一个极其艰辛的长期过程。例如，psychonautwiki的第一稿花费了整个社区从2011-2016的时间。而能够可靠坚持留下来的人少之又少，他们的工作流程也总是随他们一同离开。我们的社区不需要在5年后才拥有一个现代而开放的平台。我们昨天就需要它。

正因如此，我们从互联网各处的在线资源中仔细抓取事实知识，将其组装进机制解析器或LLM合成流水线，并汇总成一个精美的、机器可读的单一数据集，供任何人下载。在这一过程之后，我们经过数月的人工审阅才放心发布，总共耗时约一年。我们深深在意自己在这里所做的事情，如今正以人类的身份在这个新的开放标准之上继续构建。

dose.wiki目前处于beta阶段。每篇文章的Article Status部分跟踪其进展，并标明是否经过人工审阅。审阅对可信度至关重要：审阅者核实药理学内容，检查剂量和相互作用信息中是否存在潜在有害的错误，并添加更正、参考文献和自己的解释。错误可能造成严重的现实后果，因此我们欢迎任何有能力的人通过每篇物质文章底部的表单提交反馈！

其他合集则完全由人类创作：

效应文章构成Subjective Effect Index，在十多年间跨越多个网站写成。
再现作品通过艺术作品描绘体验的主观外观，大多出自Reddit的r/replications社区成员之手。
体验报告由其作者撰写，并在发布前经编辑审阅。

本网站和数据集将继续朝1.0演进。请回访查看更新，或send questions, comments, and corrections。

创始人与贡献者

支持方

文档

下载与再利用

GitHub 上的源代码公开 API

示例记录 · 每晚从实时数据库刷新

2 "id": 5,

3 "title": "1cP-MiPLA",

4 "priority": "high",

5 "index_categories": [],

6 "identification": {

7 "common_name": "1cP-MiPLA",

8 "substitutive_name": "1-Cyclopropionyl-N-methyl-N-isopropyllysergamide",

9 "iupac_name": "(6aR,9R)-4-(cyclopropanecarbonyl)-N,7-dimethyl-N-propan-2-yl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide",

10 "alternative_names": [

11 "1cP-MIPLA",

12 "Lamide (parent compound)"

13 ],

14 "smiles": "CN1C[C@@H](C=C2[C@H]1Cc1cn(c3c1c2ccc3)C(=O)C1CC1)C(=O)N(C(C)C)C",

15 "inchi_key": "",

16 "cas_number": "",

17 "molecular_formula": "C24H29N3O2",

18 "molecular_weight": "391.506 g/mol",

19 "skeletal_structure_image": "",

20 "botanical_name": ""

21 },

22 "classification": {

23 "psychoactive_class": [

24 "Psychedelic"

25 ],

26 "chemical_class": [

27 "Lysergamide"

28 ]

29 },

30 "summary": "1cP-MiPLA is a semisynthetic psychedelic of the lysergamide class that first emerged as a novel designer drug around 2020.[citation-needed] It is a structural analog of MiPLA and is suspected to act as a prodrug for that compound, though insufficient data currently exists to confirm this relationship.[citation-needed] As a research chemical with limited documented human use, its safety profile and pharmacological properties remain poorly characterized.",

31 "dosage": {

32 "routes": [

33 {

34 "route": "oral",

35 "bioavailability": "",

36 "bioavailability_notes": "",

37 "dose_ranges": {

38 "threshold": {

39 "min": 50,

40 "max": null,

41 "unit": "µg"

42 },

43 "light": {

44 "min": 100,

45 "max": 150,

46 "unit": "µg"

47 },

48 "moderate": {

49 "min": 150,

50 "max": 200,

51 "unit": "µg"

52 },

53 "strong": {

54 "min": 200,

55 "max": 250,

56 "unit": "µg"

57 },

58 "heavy": {

59 "min": 300,

60 "max": null,

61 "unit": "µg"

62 }

63 },

64 "notes": "The spacing between threshold and light dose ranges is unusually wide, reflecting the scarcity of reliable dosing data for this recently emerged compound.",

65 "reference_ids": []

66 }

67 ],

68 "plateau_dosing": null

69 },

70 "duration": {

71 "routes": [

72 {

73 "route": "oral",

74 "half_life": "",

75 "half_life_notes": "",

76 "stages": {

77 "onset": {

78 "min": 20,

79 "max": 40,

80 "unit": "minutes"

81 },

82 "come_up": {

83 "min": 45,

84 "max": 90,

85 "unit": "minutes"

86 },

87 "peak": {

88 "min": 1,

89 "max": 2,

90 "unit": "hours"

91 },

92 "offset": {

93 "min": 1,

94 "max": 2,

95 "unit": "hours"

96 },

97 "after_effects": {

98 "min": null,

99 "max": null,

100 "unit": "hours"

101 },

102 "total_duration": {

103 "min": 4,

104 "max": 6,

105 "unit": "hours"

106 }

107 },

108 "reference_ids": []

109 }

110 ]

111 },

112 "subjective_effects": {

113 "notes": {

114 "overview": "1cP-MiPLA is believed to act as a prodrug for MiPLA, and its subjective effects are correspondingly reported to closely mirror those of its parent compound. The experience is that of a classic lysergamide psychedelic in the vein of LSD, though it is generally described as gentler, shorter-lasting, and less mentally demanding than LSD itself. Formal documentation of this compound remains minimal, and its effect profile is inferred largely from user reports and its relationship to MiPLA.",

115 "sensory": "Visual effects follow the typical lysergamide pattern of color enhancement, flowing distortions, and geometric patterning, though they are commonly reported as softer and less forceful than those of LSD at comparable doses.",

116 "cognitive": "The headspace is often characterized as relatively clear and easygoing, with euphoria and an altered sense of time, and with less of the anxiety and cognitive intensity associated with LSD.",

117 "physical": "The body load is generally described as light, consisting primarily of mild stimulation alongside standard serotonergic psychedelic signs such as pupil dilation."

118 },

119 "sensory": {

120 "visual": {

121 "note": "Visual effects are characteristic of lysergamide psychedelics but are typically milder than those of LSD at equivalent doses.",

122 "subcategories": {

123 "geometry": {

124 "note": "",

125 "effects": [

126 {

127 "name": "Geometry",

128 "description": "Geometric patterning is present but generally less intricate and intense than that produced by LSD."

129 }

130 ]

131 },

132 "distortions": {

133 "note": "",

134 "effects": [

135 {

136 "name": "Drifting",

137 "description": ""

138 },

139 {

140 "name": "Tracers",

141 "description": ""

142 }

143 ]

144 },

145 "enhancements": {

146 "note": "",

147 "effects": [

148 {

149 "name": "Color enhancement",

150 "description": ""

151 }

152 ]

153 }

154 }

155 },

156 "auditory": {

157 "note": "",

158 "subcategories": {}

159 },

160 "tactile": {

161 "note": "",

162 "subcategories": {}

163 },

164 "olfactory": {

165 "note": "",

166 "subcategories": {}

167 },

168 "gustatory": {

169 "note": "",

170 "subcategories": {}

171 },

172 "multisensory": {

173 "note": "",

174 "subcategories": {}

175 }

176 },

177 "cognitive": {

178 "emotional": {

179 "note": "",

180 "effects": [

181 {

182 "name": "Euphoria",

183 "description": ""

184 }

185 ]

186 },

187 "perception": {

188 "note": "",

189 "effects": [

190 {

191 "name": "Time distortion",

192 "description": ""

193 }

194 ]

195 }

196 },

197 "physical": {

198 "stimulation": {

199 "note": "",

200 "effects": [

201 {

202 "name": "Stimulation",

203 "description": "Mild and less pronounced than the stimulation associated with LSD."

204 }

205 ]

206 },

207 "neurological": {

208 "note": "",

209 "effects": [

210 {

211 "name": "Pupil dilation",

212 "description": ""

213 }

214 ]

215 }

216 },

217 "attribution": {

218 "author": "dose.wiki AI editorial pipeline",

219 "text": "This section was synthesized from the article's collected source material by dose.wiki's AI editorial pipeline.",

220 "url": ""

221 }

222 },

223 "comparisons": [],

224 "pharmacology": {

225 "pharmacodynamics": "Direct receptor-binding and functional-activity data have not been reported for 1cP-MiPLA. The available primary study identified the substance in sheet products but did not assess its biological activity.[cite:doi-10-1007-s11419-023-00661-1]",

226 "binding_sites": [],

227 "pharmacokinetics": "No substance-specific metabolic pathway has been reported for 1cP-MiPLA.[citation-needed] Conversion to MiPLA remains a hypothesis by analogy with other N1-acyl lysergamides: conversion of 1cP-LSD to LSD has been demonstrated in human serum, but conversion of 1cP-MiPLA to MiPLA has not.[citation-needed]",

228 "metabolites": []

229 },

230 "interactions": {

231 "dangerous": [

232 "Lithium (There are a large number of reports indicating a high seizure and psychosis risk from this combination.)"

233 ],

234 "unsafe": [

235 "Tramadol (Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.)"

236 ],

237 "caution": [

238 "Amphetamines (Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences)",

239 "Cannabis (Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.)",

240 "Cocaine (Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences)",

241 "Diphenhydramine (At 25-50mg, DPH may assist with side effects of the LSD such as nausea and anxiety. At higher dosages, the combination of a deliriant (DPH) and LSD is cautioned against. LSD is likely to increase the deliriant and negative effects of DPH, in addition to increasing the risk of severe injury and mental trauma. LSD and DPH at recreational dosages have additional cardiac concerns such as vasoconstriction, tachycardia, hypertension, which in combination may be exacerbated.)",

242 "Mephedrone (The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops, in addition to the possible negative side effects of coming down from said stimulant while on a psychedelic. In extreme cases, stimulants, especially in combination can result in severe vasoconstriction, tachycardia, hypertension, and heart failure.)",

243 "Pregabalin (Caution should be given due to LSD’s stimulating effects and pregabalin’s seizure concerns at higher dosages. Pregabalin may reduce the vasoconstriction, anxiety, and other side effects of LSD. Additionally, Pregabalin may increase LSD’s inhibition and risk of injury.)"

244 ]

245 },

246 "reagent_testing": {},

247 "tolerance": {

248 "full_tolerance": "Tolerance to the effects of 1cP-MiPLA develops almost immediately following ingestion, consistent with the rapid tolerance pattern observed with other lysergamide psychedelics.",

249 "half_tolerance": "Approximately 5-7 days after use, tolerance is estimated to decrease to roughly half of its peak level.",

250 "baseline_tolerance": "Complete return to baseline tolerance typically requires around 14 days of abstinence from 1cP-MiPLA and other serotonergic psychedelics.",

251 "cross_tolerance": [

252 "Serotonergic psychedelics (LSD, psilocybin, mescaline, DMT)",

253 "Other lysergamides"

254 ]

255 },

256 "harm_potential": {

257 "addiction": {

258 "psychological": {

259 "level": "extremely_low",

260 "description": "Assumed to be non-habit-forming based on its similarity to LSD[citation-needed]; the desire to use may actually decrease with repeated administration. No formal studies have been conducted."

261 },

262 "physical_dependence": {

263 "level": "extremely_low",

264 "description": "No evidence of physical dependence potential. Like LSD, 1cP-MiPLA is not associated with withdrawal symptoms or compulsive physical need for the substance.[citation-needed]"

265 }

266 },

267 "toxicity": {

268 "organ_toxicity": [],

269 "carcinogenicity": {

270 "level": "unknown",

271 "evidence": null,

272 "description": "No carcinogenicity studies have been conducted on 1cP-MiPLA."

273 },

274 "antibiotic_function": {

275 "level": "unknown",

276 "description": "No studies on antimicrobial properties."

277 }

278 },

279 "psychosis": {

280 "level": null,

281 "description": "May act as a potential trigger for psychotic episodes in individuals with underlying psychiatric conditions or family history of mental illness.[citation-needed] Adverse psychological reactions including delusions become more likely at higher doses, though severe psychotic episodes requiring medical attention are uncommon with this substance alone."

282 },

283 "seizure": {

284 "level": null,

285 "description": "Seizures are reported rarely and are thought to mainly pose a risk in those who are genetically predisposed[citation-needed], particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment. Risk is extrapolated from seizures reported following LSD use."

286 }

287 },

288 "history_culture": {

289 "content": "1cP-MiPLA is a novel synthetic lysergamide that first emerged on online research chemical markets around 2020.[citation-needed] The compound's origins remain somewhat unclear, with unverified reports attributing its initial synthesis to either Skyler Ulrich or a chemist or group operating under the name Gerstmann. It appeared alongside several other novel lysergamide derivatives, including 1cP-AL-LAD[citation-needed], as part of a wave of new designer psychedelics entering the grey market during this period.\n\nBy 2022, the compound had been identified in Japan[cite:doi-10-1007-s11419-023-00661-1], indicating its spread beyond initial Western markets. Like many contemporary research chemicals, 1cP-MiPLA was developed and distributed primarily through online vendors catering to the research chemical community[citation-needed], with limited formal scientific investigation into its properties beyond forensic identification studies.[citation-needed]\n",

290 "sections": []

291 },

292 "legality": {

293 "international": [],

294 "countries": {

295 "Russia": {

296 "status": "Schedule I",

297 "notes": "Classified as a schedule I controlled substance under Russian drug control legislation.[cite:url-normativ-kontur-ru-document-moduleid-1-documentid-503195]"

298 },

299 "Austria": {

300 "status": "Controlled under analogue or structural rule",

301 "notes": "1cP-MiPLA is covered by NPSV Annex II no. 11 as a 9,10-didehydro-ergoline-8-carboxamide derivative. NPSV Annex III no. 11 provides illustrative lysergamide examples, but does not name 1cP-MiPLA specifically. Under NPSG, § 4(1) establishes a conduct- and intent-specific offense for producing, importing, exporting, transferring or supplying a covered NPS for another person's psychoactive use with intent to obtain an advantage (up to two years' imprisonment). The prohibition is not unqualified: mere possession or personal use is not prohibited in every circumstance.",

302 "canonicalStatus": "analog_covered",

303 "instrument": "Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Annex II no. 11; NPSG § 4(1) [cite:ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1][cite:ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-37a749][cite:ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-66706f]"

304 },

305 "Germany": {

306 "status": "Illegal",

307 "notes": "Controlled substance as of July 2021.[cite:de-npsg-anlage1-ergolene-2021] Possession, production, and distribution are prohibited.[cite:de-npsg-para3-prohibitions]"

308 },

309 "Switzerland": {

310 "status": "Controlled (Verzeichnis E)",

311 "notes": "Listed as a defined derivative of Lysergic Acid under Verzeichnis E point 263 of the controlled substances ordinance.[cite:ch-betmvv-edi-verzeichnis-e-263] Exempt when used for scientific or industrial purposes.[cite:ch-betmvv-edi-verzeichnis-e-263]"

312 },

313 "United States": {

314 "status": "Unscheduled",

315 "notes": "Not specifically scheduled under the Controlled Substances Act. However, may be prosecuted as an analogue of LSD under the Federal Analogue Act when intended for human consumption.[cite:us-21-usc-813-analogue-act]"

316 }

317 }

318 },

319 "source_citations": [

320 {

321 "name": "Isomer Design (TiHKAL/PiHKAL)",

322 "url": "https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=11316&name=1cP-MiPLA"

323 },

324 {

325 "name": "PsychonautWiki",

326 "url": "https://psychonautwiki.org/wiki/1cP-MiPLA"

327 },

328 {

329 "name": "TripSit: Drug Combinations Chart",

330 "url": "https://combo.tripsit.me/"

331 },

332 {

333 "name": "Wikipedia",

334 "url": "https://en.wikipedia.org/wiki/1cP-MiPLA"

335 }

336 ],

337 "citations": [

338 {

339 "name": "Halberstadt A.L. et al. Pharmacological characterization of novel lysergamides including MiPLA. Neuropharmacology (2020)",

340 "url": "https://pubmed.ncbi.nlm.nih.gov/32470368/"

341 },

342 {

343 "name": "Tanaka R. et al. Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products. Forensic Science International (2023)",

344 "url": "https://doi.org/10.1016/j.forsciint.2023.111594"

345 },

346 {

347 "name": "TripReport.net substance overview: 1cP-MiPLA",

348 "url": "https://tripreport.net/substances/1cP-MiPLA"

349 },

350 {

351 "name": "Wagmann L. et al. Analysis of LSD analogs (1cP-MiPLA, 1cP-LSD, etc.) in seized blotters. Forensic Toxicology (2021)",

352 "url": "https://link.springer.com/article/10.1007/s11419-021-00554-y"

353 }

354 ],

355 "references": [

356 {

357 "id": "ch-betmvv-edi-verzeichnis-e-263",

358 "type": "webpage",

359 "template": null,

360 "title": "Betäubungsmittelverzeichnisverordnung (BetmVV-EDI, SR 812.121.11), Anhang 5 Verzeichnis e, Ziff. 263 Lysergsäurederivate",

361 "authors": [],

362 "year": null,

363 "date": null,

364 "containerTitle": null,

365 "siteName": null,

366 "publisher": "Eidgenössisches Departement des Innern (EDI) / Bundesrecht (admin.ch)",

367 "volume": null,

368 "issue": null,

369 "pages": null,

370 "articleNumber": null,

371 "chapter": null,

372 "edition": null,

373 "series": null,

374 "location": null,

375 "institution": null,

376 "language": null,

377 "doi": null,

378 "pmid": null,

379 "isbn": null,

380 "url": "https://res.cloudinary.com/adminch/image/private/s--aGGgd8MH--/v1773719628/Bundespublikationen/812-121-11d.pdf",

381 "archiveUrl": null,

382 "archiveDate": null,

383 "accessedAt": null,

384 "sourceType": "unknown",

385 "quality": "high",

386 "discoverySource": "live_web_research",

387 "access": "open",

388 "supportStatus": "inspected",

389 "apaText": null

390 },

391 {

392 "id": "de-npsg-anlage1-ergolene-2021",

393 "type": "webpage",

394 "template": null,

395 "title": "Anlage NpSG — Änderung vom 03.07.2021 (Einführung Stoffgruppe 5.2 Δ9,10-Ergolene), Verordnung vom 28.06.2021 (BGBl. I S. 2231)",

396 "authors": [],

397 "year": null,

398 "date": null,

399 "containerTitle": null,

400 "siteName": null,

401 "publisher": "buzer.de (Gesetze-Änderungsdienst, Volltext mit BGBl.-Fundstellen)",

402 "volume": null,

403 "issue": null,

404 "pages": null,

405 "articleNumber": null,

406 "chapter": null,

407 "edition": null,

408 "series": null,

409 "location": null,

410 "institution": null,

411 "language": null,

412 "doi": null,

413 "pmid": null,

414 "isbn": null,

415 "url": "https://www.buzer.de/gesetz/12250/al149920-0.htm",

416 "archiveUrl": null,

417 "archiveDate": null,

418 "accessedAt": null,

419 "sourceType": "unknown",

420 "quality": "high",

421 "discoverySource": "live_web_research",

422 "access": "open",

423 "supportStatus": "inspected",

424 "apaText": null

425 },

426 {

427 "id": "de-npsg-para3-prohibitions",

428 "type": "webpage",

429 "template": null,

430 "title": "§ 3 NpSG — Unerlaubter Umgang mit neuen psychoaktiven Stoffen",

431 "authors": [],

432 "year": null,

433 "date": null,

434 "containerTitle": null,

435 "siteName": null,

436 "publisher": "Bundesministerium der Justiz",

437 "volume": null,

438 "issue": null,

439 "pages": null,

440 "articleNumber": null,

441 "chapter": null,

442 "edition": null,

443 "series": null,

444 "location": null,

445 "institution": null,

446 "language": null,

447 "doi": null,

448 "pmid": null,

449 "isbn": null,

450 "url": "https://www.gesetze-im-internet.de/npsg/__3.html",

451 "archiveUrl": null,

452 "archiveDate": null,

453 "accessedAt": null,

454 "sourceType": "unknown",

455 "quality": "high",

456 "discoverySource": "live_web_research",

457 "access": "open",

458 "supportStatus": "inspected",

459 "apaText": null

460 },

461 {

462 "id": "doi-10-1002-dta-2789",

463 "type": "journal_article",

464 "template": null,

465 "title": "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)",

466 "authors": [

467 "Brandt SD",

468 "Kavanagh PV",

469 "Westphal F",

470 "Stratford A",

471 "Odland AU",

472 "Klein AK",

473 "Dowling G",

474 "Dempster NM",

475 "Wallach J",

476 "Passie T",

477 "Halberstadt AL"

478 ],

479 "year": 2020,

480 "date": null,

481 "containerTitle": "Drug Testing and Analysis",

482 "siteName": null,

483 "publisher": null,

484 "volume": "12",

485 "issue": "6",

486 "pages": "812-826",

487 "articleNumber": null,

488 "chapter": null,

489 "edition": null,

490 "series": null,

491 "location": null,

492 "institution": null,

493 "language": null,

494 "doi": "10.1002/dta.2789",

495 "pmid": "32180350",

496 "isbn": null,

497 "url": "https://pubmed.ncbi.nlm.nih.gov/32180350/",

498 "archiveUrl": null,

499 "archiveDate": null,

500 "accessedAt": null,

501 "sourceType": "primary_literature",

502 "quality": "high",

503 "discoverySource": "live_web_research",

504 "access": "abstract_only",

505 "supportStatus": "inspected",

506 "apaText": null

507 },

508 {

509 "id": "doi-10-1002-nrc-20023",

510 "type": "journal_article",

511 "template": "unknown",

512 "title": "10.1002/nrc.20023",

513 "authors": [],

514 "year": "2004",

515 "date": null,

516 "containerTitle": null,

517 "siteName": null,

518 "publisher": null,

519 "volume": null,

520 "issue": null,

521 "pages": null,

522 "articleNumber": null,

523 "chapter": null,

524 "edition": null,

525 "series": null,

526 "location": null,

527 "institution": null,

528 "language": null,

529 "doi": "10.1002/nrc.20023",

530 "pmid": null,

531 "isbn": null,

532 "url": "https://doi.org/10.1002/nrc.20023",

533 "archiveUrl": null,

534 "archiveDate": null,

535 "accessedAt": null,

536 "sourceType": "primary_literature",

537 "quality": "medium",

538 "discoverySource": "psychonautwiki_local_rendered_reference_section",

539 "access": "unknown",

540 "supportStatus": "discovery_only",

541 "apaText": null

542 },

543 {

544 "id": "doi-10-1007-bf03161089",

545 "type": "journal_article",

546 "template": "unknown",

547 "title": "Dose-independent occurrence of seizure with tramadol",

548 "authors": [],

549 "year": "2009",

550 "date": null,

551 "containerTitle": null,

552 "siteName": null,

553 "publisher": null,

554 "volume": null,

555 "issue": null,

556 "pages": null,

557 "articleNumber": null,

558 "chapter": null,

559 "edition": null,

560 "series": null,

561 "location": null,

562 "institution": null,

563 "language": null,

564 "doi": "10.1007/BF03161089",

565 "pmid": null,

566 "isbn": null,

567 "url": "https://doi.org/10.1007/BF03161089",

568 "archiveUrl": null,

569 "archiveDate": null,

570 "accessedAt": null,

571 "sourceType": "primary_literature",

572 "quality": "medium",

573 "discoverySource": "psychonautwiki_local_rendered_reference_section",

574 "access": "unknown",

575 "supportStatus": "discovery_only",

576 "apaText": null

577 },

578 {

579 "id": "doi-10-1007-s11419-023-00661-1",

580 "type": "journal_article",

581 "template": "cite_journal",

582 "title": "Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products",

583 "authors": [

584 "Rie Tanaka",

585 "Maiko Kawamura",

586 "Sakumi Mizutani",

587 "Ruri Kikura-Hanajiri"

588 ],

589 "year": null,

590 "date": "2023",

591 "containerTitle": "Forensic Toxicology",

592 "siteName": null,

593 "publisher": null,

594 "volume": "41",

595 "issue": "2",

596 "pages": "294–303",

597 "articleNumber": null,

598 "chapter": null,

599 "edition": null,

600 "series": null,

601 "location": null,

602 "institution": null,

603 "language": null,

604 "doi": "10.1007/s11419-023-00661-1",

605 "pmid": "36809464",

606 "isbn": null,

607 "url": "https://link.springer.com/content/pdf/10.1007/s11419-023-00661-1.pdf",

608 "archiveUrl": null,

609 "archiveDate": null,

610 "accessedAt": "26 July 2025",

611 "sourceType": "primary_literature",

612 "quality": "high",

613 "discoverySource": "worker_inspected",

614 "access": "open",

615 "supportStatus": "inspected",

616 "apaText": null

617 },

618 {

619 "id": "doi-10-1016-0014-2999-94",

620 "type": "journal_article",

621 "template": "unknown",

622 "title": "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists",

623 "authors": [],

624 "year": "1994",

625 "date": null,

626 "containerTitle": null,

627 "siteName": null,

628 "publisher": null,

629 "volume": null,

630 "issue": null,

631 "pages": null,

632 "articleNumber": null,

633 "chapter": null,

634 "edition": null,

635 "series": null,

636 "location": null,

637 "institution": null,

638 "language": null,

639 "doi": "10.1016/0014-2999(94",

640 "pmid": null,

641 "isbn": null,

642 "url": "https://doi.org/10.1016/0014-2999(94",

643 "archiveUrl": null,

644 "archiveDate": null,

645 "accessedAt": null,

646 "sourceType": "primary_literature",

647 "quality": "medium",

648 "discoverySource": "psychonautwiki_local_rendered_reference_section",

649 "access": "unknown",

650 "supportStatus": "discovery_only",

651 "apaText": null

652 },

653 {

654 "id": "doi-10-1016-j-neuro-2007-04-005",

655 "type": "journal_article",

656 "template": "unknown",

657 "title": "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons",

658 "authors": [],

659 "year": "2007",

660 "date": null,

661 "containerTitle": null,

662 "siteName": null,

663 "publisher": null,

664 "volume": null,

665 "issue": null,

666 "pages": null,

667 "articleNumber": null,

668 "chapter": null,

669 "edition": null,

670 "series": null,

671 "location": null,

672 "institution": null,

673 "language": null,

674 "doi": "10.1016/j.neuro.2007.04.005",

675 "pmid": "17572501",

676 "isbn": null,

677 "url": "https://doi.org/10.1016/j.neuro.2007.04.005",

678 "archiveUrl": null,

679 "archiveDate": null,

680 "accessedAt": null,

681 "sourceType": "primary_literature",

682 "quality": "medium",

683 "discoverySource": "psychonautwiki_local_rendered_reference_section",

684 "access": "unknown",

685 "supportStatus": "discovery_only",

686 "apaText": null

687 },

688 {

689 "id": "doi-10-1016-j-toxac-2022-06-295",

690 "type": "journal_article",

691 "template": "cite_journal",

692 "title": "Analyses of LSD analogs in illegal products: The identification of 1cP-AL-LAD, 1cP-MIPLA and 1V-LSD",

693 "authors": [

694 "Rie Tanaka",

695 "Maiko Kawamura",

696 "Sakumi Mizutani",

697 "Ruri Kikura-Hanajiri"

698 ],

699 "year": null,

700 "date": "2022",

701 "containerTitle": "Toxicologie Analytique et Clinique",

702 "siteName": null,

703 "publisher": null,

704 "volume": "34",

705 "issue": "3",

706 "pages": "S171",

707 "articleNumber": null,

708 "chapter": null,

709 "edition": null,

710 "series": null,

711 "location": null,

712 "institution": null,

713 "language": null,

714 "doi": "10.1016/j.toxac.2022.06.295",

715 "pmid": null,

716 "isbn": null,

717 "url": "https://doi.org/10.1016/j.toxac.2022.06.295",

718 "archiveUrl": null,

719 "archiveDate": null,

720 "accessedAt": null,

721 "sourceType": "primary_literature",

722 "quality": "high",

723 "discoverySource": "worker_inspected",

724 "access": "abstract_only",

725 "supportStatus": "inspected",

726 "apaText": null

727 },

728 {

729 "id": "doi-10-1111-j-1755-5949-2008-00059-x",

730 "type": "journal_article",

731 "template": "unknown",

732 "title": "The Pharmacology of Lysergic Acid Diethylamide: A Review",

733 "authors": [],

734 "year": "2008",

735 "date": null,

736 "containerTitle": null,

737 "siteName": null,

738 "publisher": null,

739 "volume": null,

740 "issue": null,

741 "pages": null,

742 "articleNumber": null,

743 "chapter": null,

744 "edition": null,

745 "series": null,

746 "location": null,

747 "institution": null,

748 "language": null,

749 "doi": "10.1111/j.1755-5949.2008.00059.x",

750 "pmid": null,

751 "isbn": null,

752 "url": "https://doi.org/10.1111/j.1755-5949.2008.00059.x",

753 "archiveUrl": null,

754 "archiveDate": null,

755 "accessedAt": null,

756 "sourceType": "primary_literature",

757 "quality": "medium",

758 "discoverySource": "psychonautwiki_local_rendered_reference_section",

759 "access": "unknown",

760 "supportStatus": "discovery_only",

761 "apaText": null

762 },

763 {

764 "id": "pmid-26841800",

765 "type": "journal_article",

766 "template": null,

767 "title": "Psychedelics",

768 "authors": [

769 "Nichols DE"

770 ],

771 "year": 2016,

772 "date": null,

773 "containerTitle": "Pharmacological Reviews",

774 "siteName": null,

775 "publisher": null,

776 "volume": "68",

777 "issue": "2",

778 "pages": "264–355",

779 "articleNumber": null,

780 "chapter": null,

781 "edition": null,

782 "series": null,

783 "location": null,

784 "institution": null,

785 "language": null,

786 "doi": "10.1124/pr.115.011478",

787 "pmid": "26841800",

788 "isbn": null,

789 "url": "https://pubmed.ncbi.nlm.nih.gov/26841800/",

790 "archiveUrl": null,

791 "archiveDate": null,

792 "accessedAt": null,

793 "sourceType": "unknown",

794 "quality": "fallback",

795 "discoverySource": "existing_article_reference",

796 "access": "open",

797 "supportStatus": "inspected",

798 "apaText": null

799 },

800 {

801 "id": "pmid-35107059",

802 "type": "journal_article",

803 "template": null,

804 "title": "Adverse effects of psychedelics: From anecdotes and misinformation to systematic science",

805 "authors": [

806 "Schlag AK",

807 "Aday J",

808 "Salam I",

809 "Neill JC",

810 "Nutt DJ"

811 ],

812 "year": 2022,

813 "date": null,

814 "containerTitle": "Journal of Psychopharmacology",

815 "siteName": null,

816 "publisher": null,

817 "volume": "36",

818 "issue": "3",

819 "pages": "258–272",

820 "articleNumber": null,

821 "chapter": null,

822 "edition": null,

823 "series": null,

824 "location": null,

825 "institution": null,

826 "language": null,

827 "doi": "10.1177/02698811211069100",

828 "pmid": "35107059",

829 "isbn": null,

830 "url": "https://pubmed.ncbi.nlm.nih.gov/35107059/",

831 "archiveUrl": null,

832 "archiveDate": null,

833 "accessedAt": null,

834 "sourceType": "unknown",

835 "quality": "fallback",

836 "discoverySource": "existing_article_reference",

837 "access": "open",

838 "supportStatus": "inspected",

839 "apaText": null

840 },

841 {

842 "id": "pmid-35981469",

843 "type": "journal_article",

844 "template": null,

845 "title": "Prevalence and associations of classic psychedelic-related seizures in a population-based sample",

846 "authors": [

847 "Simonsson O",

848 "Goldberg SB",

849 "Chambers R",

850 "Osika W",

851 "Long DM",

852 "Hendricks PS"

853 ],

854 "year": 2022,

855 "date": null,

856 "containerTitle": "Drug and Alcohol Dependence",

857 "siteName": null,

858 "publisher": null,

859 "volume": "239",

860 "issue": null,

861 "pages": "109586",

862 "articleNumber": null,

863 "chapter": null,

864 "edition": null,

865 "series": null,

866 "location": null,

867 "institution": null,

868 "language": null,

869 "doi": "10.1016/j.drugalcdep.2022.109586",

870 "pmid": "35981469",

871 "isbn": null,

872 "url": "https://pubmed.ncbi.nlm.nih.gov/35981469/",

873 "archiveUrl": null,

874 "archiveDate": null,

875 "accessedAt": null,

876 "sourceType": "unknown",

877 "quality": "fallback",

878 "discoverySource": "existing_article_reference",

879 "access": "open",

880 "supportStatus": "inspected",

881 "apaText": null

882 },

883 {

884 "id": "url-admin-ch-5093-pdf",

885 "type": "webpage",

886 "template": "unknown",

887 "title": "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel,psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien: Änderung vom 2. November 2015",

888 "authors": [],

889 "year": "2015",

890 "date": null,

891 "containerTitle": null,

892 "siteName": null,

893 "publisher": null,

894 "volume": null,

895 "issue": null,

896 "pages": null,

897 "articleNumber": null,

898 "chapter": null,

899 "edition": null,

900 "series": null,

901 "location": null,

902 "institution": null,

903 "language": null,

904 "doi": null,

905 "pmid": null,

906 "isbn": null,

907 "url": "https://www.admin.ch/opc/de/official-compilation/2015/5093.pdf",

908 "archiveUrl": null,

909 "archiveDate": null,

910 "accessedAt": null,

911 "sourceType": "unknown",

912 "quality": "fallback",

913 "discoverySource": "psychonautwiki_local_rendered_reference_section",

914 "access": "unknown",

915 "supportStatus": "discovery_only",

916 "apaText": null

917 },

918 {

919 "id": "url-aipsin-com-562",

920 "type": "webpage",

921 "template": "cite_web",

922 "title": "1cP-MIPLA",

923 "authors": [],

924 "year": null,

925 "date": null,

926 "containerTitle": "АИПСИН",

927 "siteName": "АИПСИН",

928 "publisher": null,

929 "volume": null,

930 "issue": null,

931 "pages": null,

932 "articleNumber": null,

933 "chapter": null,

934 "edition": null,

935 "series": null,

936 "location": null,

937 "institution": null,

938 "language": null,

939 "doi": null,

940 "pmid": null,

941 "isbn": null,

942 "url": "https://aipsin.com/newsubstance/562/",

943 "archiveUrl": null,

944 "archiveDate": null,

945 "accessedAt": "26 July 2025",

946 "sourceType": "unknown",

947 "quality": "fallback",

948 "discoverySource": "worker_inspected",

949 "access": "open",

950 "supportStatus": "inspected",

951 "apaText": null

952 },

953 {

954 "id": "url-deadiversion-usdoj-gov-orangebook-pdf",

955 "type": "unknown",

956 "template": "unknown",

957 "title": "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)",

958 "authors": [],

959 "year": null,

960 "date": "January 2026",

961 "containerTitle": null,

962 "siteName": null,

963 "publisher": "U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division",

964 "volume": null,

965 "issue": null,

966 "pages": null,

967 "articleNumber": null,

968 "chapter": null,

969 "edition": null,

970 "series": null,

971 "location": null,

972 "institution": null,

973 "language": null,

974 "doi": null,

975 "pmid": null,

976 "isbn": null,

977 "url": "https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf",

978 "archiveUrl": null,

979 "archiveDate": null,

980 "accessedAt": null,

981 "sourceType": "unknown",

982 "quality": "fallback",

983 "discoverySource": "wikipedia_reference_cache",

984 "access": "unknown",

985 "supportStatus": "discovery_only",

986 "apaText": null

987 },

988 {

989 "id": "url-gesetze-im-internet-de-npsg-bjnr261510016-html",

990 "type": "unknown",

991 "template": null,

992 "title": "Neue-psychoaktive-Stoffe-Gesetz (NpSG) — Anlage 1",

993 "authors": [],

994 "year": null,

995 "date": null,

996 "containerTitle": null,

997 "siteName": null,

998 "publisher": "Bundesministerium der Justiz",

999 "volume": null,

1000 "issue": null,

1001 "pages": null,

1002 "articleNumber": null,

1003 "chapter": null,

1004 "edition": null,

1005 "series": null,

1006 "location": null,

1007 "institution": null,

1008 "language": null,

1009 "doi": null,

1010 "pmid": null,

1011 "isbn": null,

1012 "url": "https://www.gesetze-im-internet.de/npsg/BJNR261510016.html",

1013 "archiveUrl": null,

1014 "archiveDate": null,

1015 "accessedAt": null,

1016 "sourceType": "unknown",

1017 "quality": "high",

1018 "discoverySource": null,

1019 "access": "open",

1020 "supportStatus": "inspected",

1021 "apaText": null

1022 },

1023 {

1024 "id": "url-normativ-kontur-ru-document-moduleid-1-documentid-503195",

1025 "type": "unknown",

1026 "template": null,

1027 "title": "Постановление Правительства РФ от 30.06.1998 N 681 — Перечень наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации (ред. от 11.06.2025)",

1028 "authors": [],

1029 "year": null,

1030 "date": null,

1031 "containerTitle": null,

1032 "siteName": null,

1033 "publisher": "Правительство Российской Федерации",

1034 "volume": null,

1035 "issue": null,

1036 "pages": null,

1037 "articleNumber": null,

1038 "chapter": null,

1039 "edition": null,

1040 "series": null,

1041 "location": null,

1042 "institution": null,

1043 "language": null,

1044 "doi": null,

1045 "pmid": null,

1046 "isbn": null,

1047 "url": "https://normativ.kontur.ru/document?moduleId=1&documentId=503195",

1048 "archiveUrl": null,

1049 "archiveDate": null,

1050 "accessedAt": null,

1051 "sourceType": "unknown",

1052 "quality": "high",

1053 "discoverySource": "existing_article_reference",

1054 "access": "open",

1055 "supportStatus": "inspected",

1056 "apaText": null

1057 },

1058 {

1059 "id": "us-21-usc-813-analogue-act",

1060 "type": "webpage",

1061 "template": null,

1062 "title": "21 U.S.C. § 813 — Treatment of controlled substance analogues (Federal Analogue Act)",

1063 "authors": [],

1064 "year": null,

1065 "date": null,

1066 "containerTitle": null,

1067 "siteName": null,

1068 "publisher": "Cornell Law School, Legal Information Institute (U.S. Code)",

1069 "volume": null,

1070 "issue": null,

1071 "pages": null,

1072 "articleNumber": null,

1073 "chapter": null,

1074 "edition": null,

1075 "series": null,

1076 "location": null,

1077 "institution": null,

1078 "language": null,

1079 "doi": null,

1080 "pmid": null,

1081 "isbn": null,

1082 "url": "https://www.law.cornell.edu/uscode/text/21/813",

1083 "archiveUrl": null,

1084 "archiveDate": null,

1085 "accessedAt": null,

1086 "sourceType": "unknown",

1087 "quality": "high",

1088 "discoverySource": "live_web_research",

1089 "access": "open",

1090 "supportStatus": "inspected",

1091 "apaText": null

1092 },

1093 {

1094 "id": "ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1",

1095 "type": "webpage",

1096 "template": "cite_web",

1097 "title": "Neue-Psychoaktive-Substanzen-Verordnung (NPSV), consolidated official text, version 27 August 2026",

1098 "authors": [],

1099 "siteName": "ris.bka.gv.at",

1100 "publisher": "ris.bka.gv.at",

1101 "url": "https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007642/NPSV%2c%20Fassung%20vom%2027.08.2026.pdf",

1102 "sourceType": "unknown",

1103 "quality": "fallback",

1104 "access": "unknown",

1105 "supportStatus": "inspected"

1106 },

1107 {

1108 "id": "ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-37a749",

1109 "type": "webpage",

1110 "template": "cite_web",

1111 "title": "Neue-Psychoaktive-Substanzen-Verordnung, Anlage II (BGBl. II Nr. 106/2024)",

1112 "authors": [],

1113 "siteName": "ris.bka.gv.at",

1114 "publisher": "ris.bka.gv.at",

1115 "url": "https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf",

1116 "sourceType": "unknown",

1117 "quality": "fallback",

1118 "access": "unknown",

1119 "supportStatus": "inspected"

1120 },

1121 {

1122 "id": "ris-bka-gv-at-neue-psychoaktive-substanzen-verordnung-npsv-annex-ii-no-11-npsg-4-1-66706f",

1123 "type": "webpage",

1124 "template": "cite_web",

1125 "title": "Neue-Psychoaktive-Substanzen-Gesetz (NPSG), consolidated official text, version 27 August 2026",

1126 "authors": [],

1127 "siteName": "ris.bka.gv.at",

1128 "publisher": "ris.bka.gv.at",

1129 "url": "https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007605/NPSG%2c%20Fassung%20vom%2027.08.2026.pdf",

1130 "sourceType": "unknown",

1131 "quality": "fallback",

1132 "access": "unknown",

1133 "supportStatus": "inspected"

1134 }

1135 ],

1136 "publicRevision": "5d7ad1baf6a23fbb1f70155b941261cb875c874b231c0b3ba141627addd6e8e8",

1137 "expert_reviewed": true

1138}

dose.wiki 编辑者撰写的文字、数据模式及数据规范化工作均以 CC0 授权：它们属于公有领域。你可以自由使用和改进 CC0 内容，无需许可或署名。我们的代码是 MIT licensed。

第三方内容，如引用的文字、reagent test data、TripSit interaction data、旧版体验报告或再现作品，可能受其他条款约束。从 dose.wiki 下载的数据集不一定以 CC0 授权。

你可以按照 here 所述，将我们关于效应、物质和/或体验报告的数据集用于你自己的数据集、减害工作，或构建你自己的百科全书。

Official collaborations

Piru适用于 iPhone 和 Android 的剂量日志
Piru 是一款记录剂量和撰写体验报告的应用，支持 iPhone、Android 和 Mac，另有 Apple Watch 配套应用。它会记录你用了什么、用了多少、何时使用，根据持续时间数据绘制预估的效应曲线，并让你在场次进行中随时记录情绪和效应。场次结束后可以导出为报告，也可以直接填写 dose.wiki 的体验报告表单。

它的物质库可离线使用，数据来自 dose.wiki，并标明每个字段的来源。所有内容都保存在你的设备上，无需账号，没有广告，也不收集统计数据。它还可以导入 PsychonautWiki 应用中的日志。

Piru 由 kageroumado 和 pharmacykitty 开发。iPhone 测试版可在 TestFlight 获取；Android 版和 Mac 版可在 GitHub 免费下载。
kagerou.glass/piru 获取 iOS 和 Android 版 Piru
TripSitDangerous combination data
The interaction ratings on our substance pages come from TripSit's drug combination chart, which we import exactly as TripSit publishes it. TripSit also runs live harm reduction chat and its own substance factsheets.
tripsit.me
PRO Test KitReagent test results
The reagent testing results on our substance pages come from PRO Test Kit and are used with their permission. They show the colour each reagent should turn for a given substance, so you can check that what you have matches what you were told.
protestkit.eu